The tube in your hand was almost certainly designed for scabies. Five per cent permethrin cream, a single overnight application, wash it off in the morning, repeat in a week if needed. That protocol has cured millions of scabies cases and it is one of the most reliable things in dermatology.
Then a clinician reaches for the same tube for a rosacea patient with a heavy mite load, or an eyelid full of collarettes, and the results are inconsistent. Some patients clear beautifully. Some improve for a month and relapse. Some see the papules retreat while the flaking and the greasiness carry on exactly as before.
None of that is a failure of the drug. It is a mismatch between a scabies schedule and a completely different parasite with a completely different life cycle, living in a completely different compartment. Understanding permethrin for Demodex means separating those three things: what the molecule does, what the trials actually showed, and what the schedule on the box was designed for.
Quick answer
Permethrin is a genuine acaricide and one of very few agents with randomised trial data showing it lowers Demodex density in humans. In a double-blind trial, 5 per cent permethrin gel cut median mite density by about 97 per cent over 12 weeks, against 55 per cent for the placebo vehicle. But permethrin is not antifungal, not anti-inflammatory, and not ovicidal in any reliable sense, and the single-dose scabies schedule is wrong for a mite whose life cycle runs about 14.5 days. Permethrin for Demodex works when it is dosed against the cycle and combined with something that addresses the yeast and inflammatory layers it leaves untouched.
Median reduction in Demodex density with 5 per cent permethrin gel over 12 weeks in a double-blind randomised trial of 40 patients with bilateral papulopustular rosacea.
Median reduction achieved by the placebo vehicle in the same trial, which is the single best argument against trusting uncontrolled before-and-after reports.
Days from ovum to reproducing adult in Demodex folliculorum, the number that should set the dosing interval rather than the scabies label.
What permethrin is, and what it does to a mite
Every practical question about permethrin for Demodex follows from the mechanism, so it is worth two paragraphs.
The active ingredient in every permethrin for Demodex regimen is a synthetic pyrethroid, structurally modelled on the natural pyrethrins in chrysanthemum flowers but stabilised so it does not degrade in daylight within hours.
Its target is the voltage-gated sodium channel in arthropod nerve membranes. In normal nerve function these channels open briefly to admit sodium, then close, allowing the neuron to reset. Permethrin binds and prevents that closure. Sodium keeps flowing, the membrane cannot repolarise, and the neuron fires repetitively until neuromuscular control collapses. The mite is paralysed, then dies.
Two features make this useful for skin. Permethrin is highly lipophilic, so it partitions readily into sebum, which is exactly where the mite lives. And mammalian sodium channels bind pyrethroids far less avidly than arthropod channels do, while human skin metabolises the small absorbed fraction quickly. That combination is why a compound this neurotoxic to arthropods has such a benign safety record in people, including in infants over two months and in pregnancy.
The evidence base for permethrin for Demodex, in order of quality
The randomised trial
The most important study is Raoufinejad and colleagues, published in the Journal of the European Academy of Dermatology and Venereology in 2016. Forty patients with bilateral papulopustular rosacea received 5 per cent permethrin gel or placebo in a double-blind design over 12 weeks.
Median Demodex density fell by roughly 97 per cent in the permethrin arm. It also fell by roughly 55 per cent in the placebo arm.
That second number deserves as much attention as the first. Vehicle alone, applied twice daily for three months, more than halved the mite population. Cleansing, occlusion changes, the mechanical act of application and regression to the mean together account for a very large effect. Every uncontrolled testimonial you will ever read about any acaricide is sitting on top of that 55 per cent. It is also the reason a partial response to permethrin for Demodex is so hard to interpret without a density measurement.
The systematic review
Jacob and colleagues published a systematic review of treatments for Demodex-associated inflammatory skin conditions in Dermatologic Therapy in 2019, covering the literature from 1946. Their conclusion on this agent was straightforward: topical permethrin applied daily or twice daily was efficacious across multiple studies. Crotamiton and benzyl benzoate also performed. Metronidazole, by contrast, showed anti-inflammatory benefit without reliable acaricidal effect, which we cover in the metronidazole article.
The ocular data
A prospective trial enrolled 21 patients with blepharitis and microscopically confirmed Demodex, treating with 5 per cent permethrin cream once daily to the lashes, lids and brows for six months, with the eyes closed for thirty seconds after application. Mite counts fell steadily and stayed down across the treatment period, and blepharitis symptom scores including dryness, discharge and debris formation improved alongside.
Note the duration. Six months, not one week. And note the technique detail about keeping the eyes closed, because permethrin is irritating to the ocular surface and periocular application is off-label and should be clinician-supervised. Patients wanting a lower-risk lid option should read the eyelid wipes guide and the hypochlorous acid guide first, alongside the complete blepharitis guide.
The refractory case literature
Where permethrin for Demodex appears most consistently is in combination. Forstinger and colleagues, in the Journal of the American Academy of Dermatology in 1999, described rosacea-like demodicidosis refractory to conventional treatment resolving on oral ivermectin followed by weekly topical permethrin. That pattern, a systemic agent to reach the deep reservoir and a topical to hold the surface, recurs throughout the case series literature.
Why the scabies schedule is the wrong schedule
If you take one thing from this article about permethrin for Demodex, take this section.
This is the practical heart of the article.
Sarcoptes scabiei burrows in the stratum corneum. It is reachable by a single whole-body application, and a repeat dose at day seven catches whatever hatched from eggs laid before the first treatment. The schedule fits the biology.
Demodex does not fit that schedule at all, for three reasons.
The life cycle is longer. Spickett’s foundational 1961 work in Parasitology established the full sequence: ovum about 60 hours, larva about 36, protonymph about 72, deutonymph about 60, adult about 120. Roughly 14.5 days from egg to reproducing adult. A two-dose regimen ending at day seven covers half a generation.
The eggs are protected. Permethrin acts on nerve tissue. An ovum has no functioning nervous system to poison, and it sits deep in the follicle behind a lipid plug. Whatever survives hatches into skin that is no longer being treated.
Demodex brevis lives out of reach. D. folliculorum sits in the upper follicle. D. brevis lives deeper, inside the sebaceous gland. Topical penetration to that depth is partial at best, which is why the deep reservoir repopulates the surface after the surface has been cleared.
Every published protocol that works with permethrin for Demodex extends across weeks to months rather than days. The RCT ran 12 weeks. The ocular trial ran 6 months. The case literature uses weekly maintenance. There is no short course here.
The yeast layer permethrin for Demodex cannot touch
This is the most common source of disappointment, and it is entirely predictable from the mechanism.
Permethrin poisons arthropod sodium channels. Malassezia is a fungus. It has no sodium channels of the relevant kind and no nervous system at all. Permethrin has no antifungal activity whatsoever.
That matters because Demodex overgrowth and Malassezia overgrowth travel together with striking frequency. Karabay and Aksu Cerman found Demodex positivity in a little over half of seborrhoeic dermatitis patients against under 3 per cent of controls. The two organisms share a habitat and a food source, and Malassezia is uniquely dependent on that food source because it cannot synthesise its own long-chain fatty acids and must strip them out of your sebum using secreted lipases.
So the classic pattern after a successful course of permethrin is this: the papules and pustules settle, the itch improves, and the greasy scaling along the brows, nasolabial folds and hairline carries on unchanged. The mites went down. The yeast did not.
The fix is not more permethrin. It is a second agent aimed at the second organism, which is what the shampoo protocol article and the Demodex diet article both address from different directions.
Practical considerations and cautions
Several things separate a supervised course of permethrin for Demodex from an improvised one.
Permethrin is prescription-strength at 5 per cent in most jurisdictions for this use, and using it on the face for demodicosis is off-label almost everywhere. This is a clinician-directed therapy, not a self-directed one.
Irritation is the main adverse effect. Reported reactions include burning, stinging, pruritus, transient numbness and erythema. On a rosacea barrier that is already compromised, that matters. Many patients need alternate-night application initially, or a shorter contact time built up gradually.
It is not anti-inflammatory. Killing mites removes a trigger; it does not switch off an inflammatory cascade that is already running. If KLK5 and LL-37 signalling is established, expect to need something addressing that arm too.
Pregnancy and breastfeeding. Permethrin has one of the better safety records among topical antiparasitics in pregnancy, which is why it is first-line for scabies in that group. Facial use for demodicosis is still a discussion to have with your obstetric team.
Reinfestation is real. Pillowcases, towels, lash tools and close household contacts all matter, and clearing the face while leaving the environment untouched invites the relapse cycle described in why rosacea keeps coming back.
For practitioners
Permethrin sits in an unusual evidence position: strong mechanistic rationale, one good randomised trial with a hard parasitological endpoint, supportive systematic review data, and essentially no regulatory pathway for the indication. Compare that with lotilaner, which has an ocular licence and cleaner trial data but a narrower anatomical remit.
Dose against the life cycle, not the scabies label. Spickett’s 14.5-day figure implies a minimum of two full cycles for any meaningful assessment, and the published successes run 12 weeks to 6 months. Consider a loading phase of nightly or alternate-nightly application for four weeks, titrated to barrier tolerance, followed by a tapering maintenance interval rather than abrupt cessation.
Anticipate the ovicidal gap and the D. brevis reservoir. Where the phenotype is deep, granulomatous or relapsing, the combination pattern from the case literature, systemic ivermectin plus topical permethrin maintenance, has the most consistent record. Where the phenotype includes seborrhoeic scaling, add an antifungal arm from the outset rather than after the patient reports partial failure; the 55 per cent vehicle response in Raoufinejad means partial responses are extremely difficult to interpret without a density measure.
Document baseline density by standardised skin surface biopsy where available. Without it you are grading a rash, not a parasitological outcome.
Frequently asked questions
Does permethrin for Demodex actually kill the mites?
Yes. It is a true acaricide and one of a small number of agents with randomised human data showing a large reduction in mite density. It does not kill eggs reliably, and it reaches mites in the deep sebaceous glands only partially.
How long does permethrin take to work for Demodex?
Longer than most people expect. Published protocols run 12 weeks to 6 months. Because the mite life cycle is about 14.5 days, judging the result before four to six weeks means judging a single generation.
Can I use permethrin cream on my face?
Only under clinical supervision. Facial use for demodicosis is off-label, the 5 per cent strength is prescription in most countries, and irritation on an already compromised rosacea barrier is common. Periocular use requires particular care.
Permethrin or ivermectin for Demodex?
They are complementary rather than competing. Topical ivermectin combines acaricidal and anti-inflammatory activity in one product and is licensed for papulopustular rosacea in many countries. Permethrin has the stronger single parasitological trial result but no licence for this use. The most consistent results in refractory cases come from combining a systemic agent with topical maintenance.
Why did my flaking stay after permethrin cleared the bumps?
Because flaking is usually the yeast layer, and permethrin has no antifungal activity at all. Malassezia and Demodex commonly co-occur, and an acaricide alone leaves the fungal component running.
Where to go next
Permethrin for Demodex is one layer of a longer plan, not the whole plan. Confirm involvement first with the self-assessment guide or the clinical diagnosis article. For the non-prescription topical foundation, see tea tree oil and terpinen-4-ol and the natural remedies evidence review. For internal support alongside a topical, see supplements for Demodex. Practitioners can browse the research library.
References
- Raoufinejad K, Mansouri P, Rajabi M, Naraghi Z, Jebraeili R. Efficacy and safety of permethrin 5 per cent topical gel vs. placebo for rosacea: a double-blind randomized controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 2016;30(12):2105-2117.
- Jacob S, VanDaele MA, Brown JN. Treatment of Demodex-associated inflammatory skin conditions: a systematic review. Dermatologic Therapy. 2019;32(6):e13103.
- Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. Journal of the American Academy of Dermatology. 1999;41(5 Pt 1):775-777.
- Topical permethrin for Demodex-associated blepharitis: prospective evaluation of Demodex counts, Ocular Surface Disease Index and symptom scores over six months. Reviewed in American Academy of Ophthalmology Editors’ Choice, 2020.
- Kaiserman I. The efficacy of permethrin 5 per cent, fusidic acid 1 per cent and chloramphenicol 5 per cent for Demodex blepharitis. Barzilai Medical Center. ClinicalTrials.gov identifier NCT03105505.
- Spickett SG. Studies on Demodex folliculorum Simon (1842). I. Life history. Parasitology. 1961;51(1-2):181-192.
- Chang YS, Huang YC. Role of Demodex mite infestation in rosacea: a systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2017. PMID 28711190.
- Karabay EA, Aksu Cerman A. Demodex folliculorum infestations in common facial dermatoses: acne vulgaris, rosacea, seborrheic dermatitis. Anais Brasileiros de Dermatologia. 2020;95(2):187-193.
- Tomalik-Scharte D, Lazar A, Meins J, et al. Dermal absorption of permethrin following topical administration. European Journal of Clinical Pharmacology. 2005;61(5-6):399-404.
- Dawson TL Jr. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. Journal of Investigative Dermatology Symposium Proceedings. 2007;12(2):15-19.
- Comparison of two techniques for measuring Demodex folliculorum and Demodex brevis in rosacea patients: standardized skin surface biopsy versus direct microscopic examination. Parasitology Research. 2025.
About the author. Marina Ivakhnenko is a functional skin practitioner who works with chronic, relapsing follicular and barrier conditions, and writes the clinical education library at demodex.net/. This article is educational and is not a substitute for individual medical care. Permethrin 5 per cent is a prescription medicine in most countries and its use on facial skin or eyelids for demodicosis is off-label. Do not begin, alter or stop any prescription therapy without your own clinician.